Banco Bilbao Vizcaya Argentaria S.A. Sells 3,880 Shares of Stryker Co. (NYSE:SYK)

Banco Bilbao Vizcaya Argentaria S.A. decreased its stake in Stryker Co. (NYSE:SYK - Free Report) by 6.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 55,035 shares of the medical technology company's stock after selling 3,880 shares during the period. Banco Bilbao Vizcaya Argentaria S.A.'s holdings in Stryker were worth $19,895,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. Vanguard Group Inc. grew its holdings in Stryker by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 32,698,828 shares of the medical technology company's stock valued at $11,773,213,000 after purchasing an additional 252,188 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Stryker by 0.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 11,109,722 shares of the medical technology company's stock worth $4,000,056,000 after acquiring an additional 54,693 shares during the last quarter. FMR LLC grew its stake in Stryker by 10.0% during the 4th quarter. FMR LLC now owns 8,034,844 shares of the medical technology company's stock valued at $2,892,946,000 after purchasing an additional 727,850 shares in the last quarter. Geode Capital Management LLC increased its holdings in Stryker by 2.4% during the 4th quarter. Geode Capital Management LLC now owns 7,073,562 shares of the medical technology company's stock worth $2,539,033,000 after purchasing an additional 168,436 shares during the last quarter. Finally, Norges Bank acquired a new position in shares of Stryker in the 4th quarter valued at approximately $1,710,744,000. Institutional investors and hedge funds own 77.09% of the company's stock.

Stryker Price Performance

Shares of Stryker stock traded up $2.83 during trading on Tuesday, hitting $369.32. The stock had a trading volume of 412,353 shares, compared to its average volume of 1,352,798. The business has a fifty day moving average of $367.37 and a two-hundred day moving average of $373.51. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The firm has a market cap of $140.96 billion, a P/E ratio of 47.55, a PEG ratio of 2.93 and a beta of 0.93. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter last year, the business posted $3.46 earnings per share. On average, sell-side analysts expect that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.91%. The ex-dividend date is Monday, March 31st. Stryker's payout ratio is 43.30%.

Analysts Set New Price Targets

A number of analysts recently issued reports on SYK shares. Barclays lifted their price target on shares of Stryker from $418.00 to $443.00 and gave the stock an "overweight" rating in a research note on Monday, February 10th. Stifel Nicolaus boosted their price objective on Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a report on Wednesday, January 29th. JPMorgan Chase & Co. upped their price objective on Stryker from $420.00 to $445.00 and gave the company an "overweight" rating in a research note on Wednesday, January 29th. StockNews.com lowered Stryker from a "buy" rating to a "hold" rating in a research report on Thursday, March 6th. Finally, Truist Financial upped their price target on Stryker from $409.00 to $413.00 and gave the company a "hold" rating in a research report on Thursday, January 30th. Five investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $423.53.

Insiders Place Their Bets

In related news, Director Ronda E. Stryker sold 201,392 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by company insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.